Phentolamine is a non-selective, competitive alpha-adrenergic antagonist developed in the mid-20th century and used primarily for the management of conditions associated with excessive catecholamine activity. Its history is marked by its effectiveness in treating pheochromocytoma-related hypertensive crises, as well as in reversing local vasoconstriction caused by extravasation of vasopressor drugs. Phentolamine works by reversibly blocking alpha-1 and alpha-2 adrenergic receptors, leading to vasodilation, decreased peripheral vascular resistance, and improved blood flow. It is also used diagnostically in certain cases of suspected pheochromocytoma and in erectile dysfunction when injected intracavernosally. Due to its short duration of action and non-selective blockade, its clinical use is mainly limited to acute and specialized settings.
BRAND NAMES
Regitine (most widely known brand)
OraVerse (used in dentistry to reverse local anesthesia with vasoconstrictors)
Phentolamine Mesylate (generic formulations)
Ryzumvi (solution;ophthalmic)
MECHANISM OF ACTION
Phentolamine is a non-selective, competitive alpha-adrenergic antagonist that blocks both alpha-1 and alpha-2 receptors. By inhibiting alpha-1 receptors on vascular smooth muscle, it prevents catecholamine-induced vasoconstriction, leading to vasodilation and decreased peripheral vascular resistance, which lowers blood pressure.
PHARMACOKINETICS
Phentolamine systemic exposure was evaluated in a Phase 3 trial (MIRA-3) following topical ocular administration of a total of 3 drops, each of 0.03 mL, of phentolamine ophthalmic solution 0.75%. The peak concentration levels are achieved between 15 minutes and 1 hour after dosing with the median value of 0.45 ng/mL.
PHARMACODYNAMICS
Phentolamine is a non-selective, competitive alpha-adrenergic blocker that antagonizes both alpha-1 and alpha-2 receptors. By blocking alpha-1 receptors, it prevents catecholamine-induced vasoconstriction, leading to vasodilation and reduced peripheral vascular resistance, resulting in lowered blood pressure. Alpha-2 blockade increases norepinephrine release, which may cause reflex tachycardia. Its reversible binding and short duration make it useful in acute hypertensive crises and reversal of vasoconstriction due to extravasated vasopressors.
ADMINISTRATION
Phentolamine is administered intravenously or intramuscularly in emergency settings, and locally by injection in specific cases such as vasopressor extravasation or erectile dysfunction treatment. It must be given under medical supervision due to its potent cardiovascular effects.
DOSAGE AND STRENGTH
Typical dosing varies by indication:
For hypertensive emergencies: 5–15 mg IV or IM, repeated as needed
For vasopressor extravasation: infiltration of diluted solution around affected area
For diagnostic use: IV bolus under controlled settings
DRUG INTERACTIONS
Phentolamine may interact with antihypertensive agents, vasodilators, and alcohol, leading to additive hypotension. It may also oppose the effects of alpha-adrenergic agonists such as norepinephrine or epinephrine.
CONTRAINDICATIONS
Contraindications include hypersensitivity to phentolamine, and caution is required in patients with coronary artery disease, peptic ulcer disease, or severe hypotension.
SIDE EFFECTS
Common side effects include hypotension, tachycardia, dizziness, flushing, nasal congestion, and headache. Some patients may experience orthostatic hypotension or cardiac palpitations.
OVER DOSAGE
Phentolamine overdose primarily causes excessive alpha-adrenergic blockade, leading to marked vasodilation and severe hypotension. Patients may present with dizziness, weakness, flushing, blurred vision, syncope, and orthostatic collapse. Reflex tachycardia, palpitations, and possible arrhythmias may occur as compensatory responses. In severe cases, shock and reduced organ perfusion can develop.
TOXICITY
Phentolamine overdose may result in severe hypotension, reflex tachycardia, dizziness, syncope, and shock in extreme cases. Management is mainly supportive, including IV fluids and vasopressors if necessary. Continuous monitoring is required until hemodynamic stability is restored.
